title: Recommendations for the management of adult chronic myeloid leukaemia in South Africa.
abstract: BACKGROUND
  Chronic myeloid leukaemia (CML) is a chronic myeloproliferative disorder characterised by a chromosomal translocation between the long arms of chromosomes 9 and 22 [corrected] resulting in the formation of the BCR-ABL fusion gene. The management of CML has undergone major changes over the past decade. Novel treatment approaches have had a dramatic impact on patient outcomes and survival. Nevertheless, these outcomes can only be achieved in the context of expert management, careful monitoring of disease response, appropriate management of adverse events and timeous adjustments to therapy when responses are not achieved within stated time-frames.
  
  
  OBJECTIVE
  With the advent of novel treatments providing molecular responses, both the monitoring and management of CML have become more complicated. The aim of these recommendations was to provide a pragmatic yet comprehensive roadmap to negotiate these complexities.
  
  
  METHODS
  Recommendations were developed based on local expert opinion from both the academic and private medical care arenas after careful review of the relevant literature and taking into account the most widely used international guidelines. About five meetings were held at which these recommendations were discussed and debated in detail.
  
  
  RESULTS
  A comprehensive set of recommendations was compiled with an emphasis on diagnosis, investigation, treatment and monitoring of disease. Careful attention was given to circumstances unique to South Africa, funding constraints, availability and access to laboratory resources, as well as the effects of concurrent HIV infection.
  
  
  CONCLUSIONS
  Most patients with CML can live a reasonably normal life if their disease is appropriately managed. These recommendations should be of value to all specialists involved in the treatment of haematological disorders.
authors.affiliation: Division of Clinical Haematology, Department of Internal Medicine, University of the Free State, Bloemfontein. louwvj@ufs.ac.za
authors.forename: V J
authors.initials: VJ
authors.lastname: Louw
authors.forename: L
authors.initials: L
authors.lastname: Dreosti
authors.forename: P
authors.initials: P
authors.lastname: Ruff
authors.forename: V
authors.initials: V
authors.lastname: Jogessar
authors.forename: D
authors.initials: D
authors.lastname: Moodley
authors.forename: N
authors.initials: N
authors.lastname: Novitzky
authors.forename: M
authors.initials: M
authors.lastname: Patel
authors.forename: A
authors.initials: A
authors.lastname: Schmidt
authors.forename: P
authors.initials: P
authors.lastname: Willem
mesh_terms: D000328:Adult; D001549:Benzamides; D015897:Comorbidity; D000069439:Dasatinib; D019468:Disease Management; D015658:HIV Infections / Q000453:epidemiology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy*; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use; D013019:South Africa; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; C498826:nilotinib; D000069439:Dasatinib